4 - Definitive Healthcare Corp. (0001861795) (Issuer)

4 - Definitive Healthcare Corp. (0001861795) (Issuer)

4 - Definitive Healthcare Corp. (0001861795) (Issuer)

4 - Definitive Healthcare Corp. (0001861795) (Issuer)

4 - Definitive Healthcare Corp. (0001861795) (Issuer)

4 - Definitive Healthcare Corp. (0001861795) (Issuer)

4 - Definitive Healthcare Corp. (0001861795) (Issuer)

4 - Definitive Healthcare Corp. (0001861795) (Issuer)

4 - Definitive Healthcare Corp. (0001861795) (Issuer)

4 - Definitive Healthcare Corp. (0001861795) (Issuer)

FRAMINGHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2024.  Third Quarter 2024 Financial Highlights: Revenue was $62.7 million, a decrease of 4% from $65.3 million in Q3 2023. Net Loss, inclusive of goodwill impairment charges of $228.2 million, was $(187.8) million, or (300%) of revenue, down 24% compared to $(248.7) million, inclusive of goodwill impairment charges of $287.4 million, or (381%) of revenue in Q3 2023.Adjusted Ne

FRAMINGHAM, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its third quarter ended September 30, 2024, on Thursday, November 7, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international).

FRAMINGHAM, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended June 30, 2024.  Second Quarter 2024 Financial Highlights: Revenue was $63.7 million, an increase of 5% from $61.0 million in Q2 2023. Net Loss, inclusive of goodwill impairment charges of $363.6 million, was $(306.2) million, or (480%) of revenue, up 2,538% compared to $(11.6) million, or (19%) of revenue in Q2 2023.  Adjusted Net Income was $14.2 million, compared to $12.4 million in Q2 2023.   Adjusted EBITDA was $20.9 million, up 21% from

FRAMINGHAM, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its second quarter ended June 30, 2024, on Monday, August 5, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly

FRAMINGHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2024.  First Quarter 2024 Financial Highlights: Revenue was $63.5 million, an increase of 7% from $59.2 million in Q1 2023. Net Loss was $(12.7) million, or (20%) of revenue, compared to $(16.0) million, or (27%) of revenue in Q1 2023.  Adjusted Net Income was $13.0 million, compared to $9.1 million in Q1 2023.   Adjusted EBITDA was $20.0 million, or 32% of revenue, compared to $15.7 million, or 26% of revenue in Q1 2023.  Cash Flow

FRAMINGHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its first quarter ended March 31, 2024, on Tuesday, May 7, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly a

Fourth quarter revenue grew 9% year-over-year to $65.9 million Full year 2023 revenue grew 13% year-over-year to $251.4 million  FRAMINGHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2023.  Fourth Quarter 2023 Financial Highlights: Revenue was $65.9 million, an increase of 9% from $60.6 million in Q4 2022. Net (Loss) Income was ($13.4) million, or (20)% of revenue, compared to $5.9 million, or 10% of revenue in Q4 2022.  Adjusted Net Income was $10.6 million, compar

FRAMINGHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its fourth quarter and full year ended December 31, 2023, on Wednesday, February 28, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (

Jason Krantz, Founder and Executive Chairman, to Serve as Interim CEO Company Reaffirms Fourth Quarter 2023 Guidance and Issues Preliminary Guidance for 2024 FRAMINGHAM, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH) (the "Company"), an industry leader in healthcare commercial intelligence, today announced that Robert Musslewhite has stepped down as Chief Executive Officer and as a member of the Board of Directors to transition to a new phase of leadership for the Company. Jason Krantz, Founder and Executive Chairman of Definitive Healthcare, has been appointed interim Chief Executive Officer. The Board has engaged a leading global executive search firm to co

FRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2023.  Third Quarter 2023 Financial Highlights: Amounts referencing Q3 2022 and trailing twelve-month periods (excluding revenue) are as restated Revenue was $65.3 million, an increase of 14% from $57.4 million in Q3 2022. Net loss was ($248.7) million, or 381% of revenue, compared to ($6.9) million, or 12% of revenue in Q3 2022.  Adjusted Net Income was $14.6 million, compared to $8.8 million in Q3 2022.   Adjusted EBITDA was

Definitive Healthcare (NASDAQ:DH), a leader in healthcare commercial intelligence, today announced the launch of a redesigned mobile app for its popular View Suite platform. The new DH View Suite mobile app provides sales and marketing professionals with on-demand access to vital data and intelligence, maximizing their efficiency and success in the field.

Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that its Board of Directors has appointed Kevin Coop as the Company's next Chief Executive Officer and as a member of the Board of Directors, each effective June 24, 2024. Mr. Coop succeeds Jason Krantz, founder and Executive Chairman, who has been serving as Interim CEO since January 2024. Mr. Krantz will continue to serve on the Board of Directors as Executive Chairman after the CEO transition.

Deutsche Bank analyst George Hill maintains Definitive Healthcare (NASDAQ:DH) with a Hold and lowers the price target from $10 to $7.

Barclays analyst Saket Kalia maintains Definitive Healthcare (NASDAQ:DH) with a Equal-Weight and lowers the price target from $11 to $7.

Tuesday, Definitive Healthcare Corp (NASDAQ:DH) reported first-quarter adjusted EPS of $0.08, up from $0.06 a year ago, in line with the consensus. The company reported sales of $63.48 million, up 7%, missing the consensus of $63.99 million. Adjusted EBITDA was $20 million, or 32% of revenue, compared to $15.7 million, or 26% of revenue in Q1 2023.   In the first quarter, Definitive Healthcare grew its enterprise customer base by 30 or 6% Y/Y, ending with 559 enterprise customers. Guidance: Definitive Healthcare sees second-quarter revenues of $62M– $63.5M versus a consensus of $65.19 million. The company forecasts second-quarter adjusted EPS of $0.08–$0.09 versus a consensus

Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial results and issued second-quarter revenue guidance below estimates. Upstart reported first-quarter revenue of $128 million, which beat the consensus estimate of $124.867 million, according to Benzinga Pro. Upstart expects second-quarter revenue of approximately $125 million versus estimates of $140.83 million. The company anticipates a second-quarter adjusted EBITDA loss of approximately $25 million. Upstart shares dipped 10.3% to $21.96 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Reborn Coffee, In

Canaccord Genuity analyst David Hynes maintains Definitive Healthcare (NASDAQ:DH) with a Hold and lowers the price target from $10 to $8.

Gainers MaxCyte (NASDAQ:MXCT) shares rose 26.5% to $4.97 during Wednesday's regular session. The company's market cap stands at $519.4 million. The company's, Q1 earnings came out yesterday. Elanco Animal Health (NYSE:ELAN) stock moved upwards by 25.25% to $16.93. The market value of their outstanding shares is at $8.3 billion. The company's, Q1 earnings came out today. Globus Medical (NYSE:GMED) shares rose 22.17% to $62.75. The company's market cap stands at $8.4 billion. The company's, Q1 earnings came out yesterday. Clover Health Investments (NASDAQ:CLOV) stock moved upwards by 20.63% to $0.89. The company's market cap stands at $442.6 million. As per the press release, Q1 earnings c

Throughout the last three months, 4 analysts have evaluated Definitive Healthcare (NASDAQ:DH), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 3 0 0 Last 30D 1 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 2 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $9.88, a high estimate of $11.00, and a low estimate of $9.00. Experiencing a 4.82% decline, the cu

FRAMINGHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2024.  Third Quarter 2024 Financial Highlights: Revenue was $62.7 million, a decrease of 4% from $65.3 million in Q3 2023. Net Loss, inclusive of goodwill impairment charges of $228.2 million, was $(187.8) million, or (300%) of revenue, down 24% compared to $(248.7) million, inclusive of goodwill impairment charges of $287.4 million, or (381%) of revenue in Q3 2023.Adjusted Ne

FRAMINGHAM, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its third quarter ended September 30, 2024, on Thursday, November 7, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international).

FRAMINGHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (NASDAQ:DH), a leader in healthcare commercial intelligence, today announced the launch of Monocl Conferences. This solution is designed to enhance conference planning and participation for life science organizations by providing medical affairs, marketing, and conference planning teams with rich, contextualized conference data and access to the experts driving conference activities. By delivering a comprehensive overview of key conference insights—including information about presenters, timing, and locations of the most relevant scientific and medical updates—Monocl Conferences can help biopharma and medtech organ

FRAMINGHAM, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (NASDAQ:DH), a leader in healthcare commercial intelligence, today announced the launch of Market Forecast, a powerful predictive analytics solution designed to help healthcare organizations uncover high-growth markets and service line opportunities to strengthen investments and partnerships. Delivering year-over-year growth rate and market demand projections up to 10 years out, Market Forecast enables business development teams, service line leaders, and strategy executives to see ahead to drive improved patient acquisition and retention, market expansion, and better resource allocation. "As an academic medical ce

FRAMINGHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that its Chief Financial Officer, Rick Booth, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference. The Definitive Healthcare presentation is scheduled for Thursday, September 5, 2024, at 8:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Events page of the Definitive Healthcare investor relations website at https://ir.definitivehc.com/. A replay of the webcast will also be available for a limited time. About Definitive HealthcareAt Definitiv

FRAMINGHAM, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (NASDAQ:DH), a leader in healthcare commercial intelligence, today announced the expansion of its Population Intelligence platform to a broader range of industries selling into healthcare. Building on its success in offering healthcare provider organizations patient and consumer analytics, Population Intelligence now supports businesses in additional sectors—such as advertising, marketing, telehealth, staffing, and medical supply—to drive stronger performance for marketing campaigns and digital advertising. "A deep understanding of our target markets is crucial for our success. With Population Intelligence, we can

FRAMINGHAM, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended June 30, 2024.  Second Quarter 2024 Financial Highlights: Revenue was $63.7 million, an increase of 5% from $61.0 million in Q2 2023. Net Loss, inclusive of goodwill impairment charges of $363.6 million, was $(306.2) million, or (480%) of revenue, up 2,538% compared to $(11.6) million, or (19%) of revenue in Q2 2023.  Adjusted Net Income was $14.2 million, compared to $12.4 million in Q2 2023.   Adjusted EBITDA was $20.9 million, up 21% from

FRAMINGHAM, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its second quarter ended June 30, 2024, on Monday, August 5, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly

FRAMINGHAM, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (NASDAQ:DH), a leader in healthcare commercial intelligence, today announced the launch of a redesigned mobile app for its popular View Suite platform. The new DH View Suite mobile app provides sales and marketing professionals with on-demand access to vital data and intelligence, maximizing their efficiency and success in the field. "In today's healthcare sales environment, access to on-demand information is the ultimate competitive advantage," said Leah Shea, VP of Product at Definitive Healthcare. "The DH View Suite mobile app gives our customers the power to transform every moment into a productive opportunity,

FRAMINGHAM, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that Definitive Healthcare's Board of Directors (the "Board") granted inducement awards consisting of 1,137,038 performance-based restricted stock units ("PSUs") and 1,170,047 time-based restricted stock units ("RSUs") to Kevin Coop, Definitive Healthcare's new Chief Executive Officer and member of the Board, effective June 24, 2024. The awards were granted as an inducement material to Mr. Coop's commencement of employment with Definitive Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4). The awards are subject to the